TotalMarketCap

Coherus Oncology

CHRSNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$115.891 M

$0.75 -11.77%

Close of 6 Nov 2026

As of 6 Nov 2026, Coherus Oncology (CHRS) has a market capitalization of $115.9M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

$168.0M

#1068 by earnings

Shares outstanding

154,500,966

Latest filing cover page

P/E ratio

0.7

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #103Compass TherapeuticsCMPX$125.1M
  2. #104Molecular PartnersMOLN$120.6M
  3. #105Coherus OncologyCHRS$115.9M
  4. #106enGene TherapeuticsENGN$113.6M
  5. #107Cardiol TherapeuticsCRDL$112.1M

What if Coherus Oncology were worth as much as…

Open the what-if tool →

Gold $28.2T

$182,761.79

Per share 243,650× higher

Bitcoin $1.53T

$9,888.92

Per share 13,183× higher

Apple $5.02T

$32,464.41

Per share 43,280× higher

Or at a round number

$200.0M$500.0M$1.00B$2.00B

Where these numbers come from

Share counts and financials for Coherus Oncology are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.